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An impaired anti-tumor immunity is found in patients
with cancer and represents a major obstacle in the suc-
cessful development of different forms of immunotherapy.
Several pathways have been described to explain the
induction of T cell anergy in tumors; however, the transla-
tion of this understanding into new adjuvants for immu-
notherapy has been limited. Pharmacological inhibition of
Notch-homolog-related proteins (Notch) in T cells leads
to a similar inhibitory effect to that found in tumors.
Thus, we aimed to determine the role of Notch in the
function of T cells and to test the effect of the transgenic
expression of Notch 1 intracellular active domain (N1IC)
in a tumor model of T cell-based immunotherapy. Our
results show an increased expression of Notch 1 and 2,
but not Notch 3 and 4, in activated CD4+ and CD8+
T cells. In addition, conditional deletion of both Notch 1
and 2 in antigen-specific CD4+ and CD8+ T cells, but not
individual deletion of Notch forms, prevented cell prolif-
eration and IFNg production. Interestingly, tumor-asso-
ciated myeloid-derived suppressor cells (MDSC) inhibited
the expression of Notch 1/2 in activated T cells at the
same ratios at which they blocked T cell proliferation and
IFNg production. To address the relevance of the
decreased expression of Notch in T cells in tumor-induced
tolerance, we adoptively transferred antigen-specific CD8+
T cells over-expressing N1IC (OT-1 N1ICf/f Gnz-Cre+/-)
or floxed controls, into mice bearing established 3LL
tumors carrying the model antigen ovalbumin (OVA).
A higher anti-tumor effect and IFNg production was
observed in tumor-bearing mice transferred with N1IC
CD8+ cells, as compared to those receiving floxed cells.
Then, we tested whether N1IC directly promoted T cell
cytotoxicity. An increased antigen-specific killing against
OVA-loaded cells was induced by N1IC CD8+ cells in
vitro and in vivo, as compared to control cells. This effect
correlated with an increased expression in N1IC CD8+
T cells of the degranulation marker CD107a and the effec-
tor molecules granzyme B and IFNg. Interestingly, N1IC
endogenously bound to granzyme B promoter, suggesting
a direct role of N1IC in the induction of effector genes in
T cells. Moreover, an increased expression of T cell survi-
val receptors CD122, IL-7R, and CD44 was found in N1IC
mice, suggesting a potential role of Notch signaling in
T cell survival/stemness. Altogether, these results suggest
the role of Notch-1/2 in T cell function and the potential
use of N1IC as an adjuvant for T cell-based immunother-
apy. Continuation of this work could enable the design of
new therapeutic approaches to reverse T cell anergy in
individuals with cancer.
Published: 7 November 2013
doi:10.1186/2051-1426-1-S1-O13
Cite this article as: Sierra et al.: Transgenic expression of Notch-1
intracellular active domain (N1IC) in T cells: a potential therapy to
overcome suppression induced by tumors. Journal for ImmunoTherapy of
Cancer 2013 1(Suppl 1):O13.
Stanley S. Scott Cancer Center, Louisiana State University, New Orleans, LA,
USA
Sierra et al. Journal for ImmunoTherapy of Cancer 2013, 1(Suppl 1):O13
http://www.immunotherapyofcancer.org/content/1/S1/O13
© 2013 Sierra et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
